Kelly Ann Roby

Title: Kelly Ann Roby: Innovator in Antibody-Drug Conjugate Formulations

Introduction

Kelly Ann Roby is a prominent inventor based in Bloomington, IN (US). She has made significant contributions to the field of antibody-drug conjugates, with a focus on developing innovative formulations that enhance the efficacy of therapeutic agents.

Latest Patents

Roby holds 2 patents that showcase her expertise in this area. Her latest patents include "Formulation for antibody and drug conjugate thereof," which discloses surfactant-free antibody and ADC formulations for anti-AXL antibodies and ADCs. These formulations are particularly suitable for an anti-AXL ADC based on an auristatin or DM1 derivative, as well as other similarly hydrophobic drugs. The formulations often comprise histidine and mannitol. Another notable patent is "Lyophilized anti-tissue factor antibody-drug conjugates," which presents surfactant-free lyophilized formulations of ADCs, such as anti-tissue factor ADCs. These formulations are designed for reconstitution and include excipients like histidine, sucrose, trehalose, mannitol, and glycine.

Career Highlights

Roby is currently associated with Genmab A/S, where she continues to push the boundaries of research in antibody-drug conjugates. Her work is instrumental in developing formulations that improve the stability and effectiveness of these therapeutic agents.

Collaborations

Throughout her career, Roby has collaborated with notable colleagues, including Timothy Warren Paul and Gregory Allan Sacha. These partnerships have contributed to her innovative research and development efforts.

Conclusion

Kelly Ann Roby is a trailblazer in the field of antibody-drug conjugate formulations, with a strong focus on creating effective and stable therapeutic solutions. Her contributions are paving the way for advancements in medical treatments.